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Introduction
Nontuberculous mycobacterial pulmonary diseases (NTM-PD) are increasingly recognised 
as opportunistic infections of humans. These chronic pulmonary infections have two main 
presentations. The first is a fibro-cavitary disease, that occurs in patients with pre-existing 
pulmonary diseases, such as chronic obstructive pulmonary disease, bronchiectasis, previous 
tuberculosis or other structural lung disease. The second presentation is a nodular-
bronchiectatic disease of primarily the lingula and middle lobe that tends to affect a middle-
aged and elderly female population [1].
Treatment of NTM-PD requires long-term administration of complex multidrug therapies 
that are species-specific. Currently recommended regimens are supported by a very limited 
evidence base [2, 3]. The increasing incidence of NTM-PD has sparked increased interest in 
performing prospective randomised clinical trials [4]. One of the drawbacks of the existing 
case series and clinical trials is that they have applied different outcome measures [5]. This 
hampers meta-analyses, which are important in these still understudied infectious diseases.
To enhance the quality and interpretability of the results of future trials and retrospective 
cohort studies, we aimed to formulate clear and broadly acceptable outcome definitions for 
NTM-PD treatment.
Methods
Critical outcome parameters were selected and their draft definitions were produced during 
two meetings (Copenhagen, April 2015; San Diego, October 2015) of the American 
Thoracic Society/European Respiratory Society/Infectious Diseases Society of America/
European Society of Clinical Microbiology and Infectious Diseases committee writing the 
upcoming guidelines on diagnosis and treatment of NTM-PD, and during the 4th biannual 
NTM-NET meeting (Amsterdam, September 2015). During these meetings, present panel 
members were asked to formulate what they considered key outcome parameters that 
required definitions. Then, panel members were asked to come up with possible definitions 
and their potential limitations. The lead author ( J. van Ingen) took notes during these 
meetings and selected the outcome parameters and prepared the first draft definitions from 
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these notes. Four additional experts within NTM-NET (T. Aksamit, W-J. Koh, K. Morimoto, 
R. Thomson) were then counselled to ensure a broader and geographically more diverse 
group.
A five-round revision and voting process was initiated, following previously used 
methodology [6]. The outcome definitions were developed in this stepwise mechanism:
Step 1:
Preliminary definitions, drafted by the lead author during the meetings, were shared with 
panel members, with an invitation to send in alternatives.
Step 2:
Alternative definitions were collected by the coordinating author.
Step 3:
All panel members and the additional NTM-NET experts were asked to select one preferred 
definition from those drafted in steps 1 and 2. The vote was blinded to all other participants.
Step 4:
For each definition, the one that received most votes was selected for inclusion in this 
statement.
Step 5:
All participants were asked to indicate their agreement or disagreement with the selected 
definition. Results of the decisions are indicated at the end of each definition.
All voting procedures were managed by the lead author ( J. van Ingen) and performed by e-
mail, with ballots prepared using Microsoft Excel software. All votes were counted 
independently by lead and senior authors (J. van Ingen, D. Wagner). Definitions were 
accepted if agreement of >80% of the participants was reached.
Results
23 NTM-NET members participated in writing this statement. For each parameter, the 
complete list of possible definitions sent out for voting in Step 3 is presented in table 1. The 
final definitions are presented in bold face in table 1, with the results of voting in step 4 and 
the extent of consensus achieved in step 5.
Discussion
To improve the quality in reporting and enable meta-analyses of clinical studies, we are now 
proposing consensus definitions for key outcome parameters to be used in the treatment of 
NTM-PD. These definitions can also aid in the design of future clinical trials for new 
treatment regimens.
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Consensus on the definition for cure proved hardest to obtain due to the risk of reinfection in 
patients with NTM-PD. For other diseases, including tuberculosis (TB), the term “cure” is 
reserved for patients remaining disease-free for a specified period after the end of treatment 
[6, 7]. For NTM this is more complicated; (clinical) cure is based on a decrease in, rather 
than full resolution of, symptoms, because of underlying lung diseases and exposure to the 
causative agents is likely commonplace owing to their ubiquity in the environment [1, 2]. 
Typing tools to distinguish relapses from reinfections and thus to offer feedback on 
treatment effect are not widely available yet and have not been standardised and validated 
[8]. Hence, for now, adding a disease-free period after treatment cessation to define cure did 
not obtain a majority of expert votes. Aware of this limitation, we propose to use the end of 
treatment as the moment to define cure. In the future, with validated biomarkers of disease 
and tools for strain typing, the definition of cure may include a period of disease-free 
survival with negative cultures.
There was very high agreement for definitions other than for cure, although the vote in step 
3 did not always yield a clear favourite. Some draft definitions varied only in details (e.g. 
one or two positive cultures; table 1); in absence of any evidence in favour of either option, 
having agreed-upon definitions was perhaps considered as important as their exact details.
Applying these definitions, a single positive culture after culture conversion does not yet 
mean treatment failure. This stresses the importance of requesting repeated follow-up 
cultures after culture conversion and end of treatment. Sputum induction or bronchoscopy, 
perhaps with computed tomography imaging for guidance, may be required to obtain good 
quality respiratory specimens to determine treatment outcome. Essentially, a single positive 
culture after culture conversion equals that of a single positive culture at the time of first 
diagnosis [2].
The next challenge is how to convert these definitions into uniform clinical practice. A 
pressing issue is what to do when patients meet the definition for failure. Is that the point 
when a switch to a second-line regimen is warranted? The timing set out in the current 
definition, after 12 months of treatment, may be regarded by some to be too conservative. 
One may question whether it is ethical to wait that long in patients still culture positive after 
6 months of guideline-compliant NTM-PD treatment. In addition, this timing aspect may be 
different for disease caused by different NTM species or for different disease manifestations, 
i.e. fibro-cavitary disease versus nodular-bronchiectatic disease. In multidrug-resistant TB, a 
manifestation of TB that shares similar features to NTM-PD in respect to management, 
adverse events of therapy, prognosis and costs, a positive culture status at 6 months of 
therapy has recently been suggested to define failure [9]. The recent study on semi-
quantitative cultures to monitor treatment effect suggests that a lack of microbiological 
response after 6 months of treatment is a very accurate predictor of treatment failure (non-
response) at 12 months and beyond [10], and this time point has thus been chosen in 
ongoing clinical trials in failing patients [4]; on the other hand, culture conversion after 
month 6 certainly does occur [11, 12].
Proper use of these outcome definitions does set requirements for standards of care for 
NTM-PD patients. For example, to effectively monitor culture conversion and 
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(microbiological) cure requires submission of multiple good-quality sputum samples, but 
may also require computed tomography (CT) imaging and guided bronchoscopy for 
bronchoalveolar lavage (BAL) specimens, at set times during and after the entire course of 
treatment. Also, monitoring improvement in symptoms and signs to establish clinical cure 
requires the use of validated instruments to measure these. The recent recommendations on 
diagnosis and treatment of NTM-PD in cystic fibrosis patients provide pragmatic schemes to 
set these standards [3]. Nonetheless, standards of care specific to NTM-PD and relevant to 
all patients would still be helpful.
These definitions and the process by which they were set have some important limitations. 
First, these definitions result from a debate that included expert pulmonologists, infectious 
disease physicians, microbiologists and a patient representative. Thus, the process and its 
outcomes are based on expert opinion rather than a systematic review of the literature, a 
shortcoming also noted for the TB-NET document [4] from which the methodology was 
derived [13]. This methodology was chosen for its pragmatism, in a field devoid of data to 
support weighing of relevance of outcomes based on systematic review. This method also 
introduces selection bias as most members of this NTM-NET committee are in frequent 
contact and this may have already introduced uniformity in the definition and use of 
outcome parameters; also, four panel members joined after the initial drafting, hence could 
only vote, not draft. Second, these outcome definitions reflect the outcomes of current 
treatment regimens. With the advent of new treatment modalities for NTM-PD, including 
new antibiotics, time to sputum culture conversion may be shortened and this could affect 
the definition of treatment failure. Third, in the absence of other validated biomarkers for 
treatment response, these definitions rely heavily on culture of respiratory specimens. This is 
problematic in patients who do not produce sputum and may require CT imaging, guided 
bronchoscopy and the acquisition of BAL fluid specimens to determine culture conversion 
and cure, as stated in the recent British Thoracic Society guidelines on NTM-PD 
management [14]. Non-culture-based biomarkers for diagnosis and treatment response 
remain urgently needed. Radiological improvement as a marker is helpful but does not, by 
definition, follow the clinical and microbiological response to treatment [15, 16]. Fourth, 
molecular detection of NTM directly in clinical specimens is still not commonplace, but is 
likely to become routine in the upcoming years [17]. The interpretation of its results and 
how these affect current outcome definitions should be subject of future studies. Last, for 
many (especially retrospective) studies, the data gathered will not allow use of all outcomes 
defined here. For example, the distinction of recurrences into relapses and reinfections 
requires molecular typing data.
In summary, we have achieved international expert consensus on treatment outcome 
definitions for NTM-PD, using a five-round drafting and voting process. There was very 
high agreement among experts for all outcome definitions with the exception of the 
definition for cure. Definitions will need to be re-evaluated when more longitudinal clinical 
data on NTM-PD become available. We encourage the application of these definitions in 
both clinical management and in future studies and their design. Uniform outcome measures 
and reports will facilitate meta-analyses of trials and case series, which in turn will increase 
the quality of evidence available to support treatment regimens for these difficult-to-treat 
infections.
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1 The finding of at least two consecutive negative mycobacterial cultures from respiratory samples during 
antimycobacterial treatment (the sampling date of the first negative culture is then the date of culture 
conversion)
0
2 The finding of at least two consecutive negative mycobacterial cultures from respiratory samples, 
collected at least 4 weeks apart, during antimycobacterial treatment (the sampling date of the first 
negative culture is then the date of culture conversion)
6
3 The finding of at least two consecutive negative mycobacterial cultures from respiratory samples, 
collected at least a day apart, during antimycobacterial treatment (the sampling date of the first negative 
culture is then the date of culture conversion)
2
4 The finding of at least three consecutive negative mycobacterial cultures from respiratory samples during 
antimycobacterial treatment (the sampling date of the first negative culture is then the date of culture 
conversion)
6
5 The finding of at least three consecutive negative mycobacterial cultures from respiratory samples, 
collected at least 4 weeks apart, during antimycobacterial treatment (the sampling date of the first 
negative culture is then the date of culture conversion)
9 22/23 (96%)
Microbiological cure
1 Finding multiple consecutive negative but no positive cultures with the causative species from 
respiratory samples after culture conversion and until the end of antimycobacterial treatment
9 22/23 (96%)
2 Finding multiple consecutive negative but no positive cultures with the causative species from respiratory 
samples after culture conversion and at the end of antimycobacterial treatment
6
3 Permanent culture conversion that is maintained after therapy cessation 8
Cure
1 Antimycobacterial treatment completed, with documented culture conversion and without any evidence 
of failure or recurrence until 24 months after the end of antibiotic treatment
3
2 Negative culture status 6 months after treatment initiation, no positive culture thereafter and being 
relapse-free 1 year after treatment completion
3




1 Patient-reported and/or objective improvement of symptoms during antimycobacterial treatment, 
sustained until at least the end of treatment, but no cultures available to prove culture conversion or 
microbiological cure
11 21/23 (91%)
2 Patient-reported and/or objective improvement of symptoms during antimycobacterial treatment, 
sustained until at least the end of treatment, but no cultures obtainable to prove culture conversion or 
microbiological cure
3
3 Patient-reported and/or objective improvement of symptoms during antimycobacterial treatment, 
sustained until at least 24 months after the end of antibiotic treatment
7
4 Patient-reported and/or objective resolution of signs and symptoms during antimycobacterial treatment, 




1 The re-emergence or persistence of positive cultures with the causative species from respiratory samples 
after ⩾12 months of antimycobacterial treatment, while the patient is still on treatment
6
2 The re-emergence of multiple positive cultures or persistence of positive cultures with the causative 
species from respiratory samples after ⩾12 months of antimycobacterial treatment, while the patient is 
still on treatment
14 23/23
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1 The re-emergence of positive cultures with the causative species from respiratory samples within 24 
months after cessation of antimycobacterial treatment
3
2 The re-emergence of at least two positive cultures with the causative species from respiratory samples 
after cessation of antimycobacterial treatment
15 21/23 (91%)




1 The emergence of multiple positive cultures with the same strain of the causative species after treatment 3
2 The emergence of at least two positive cultures with the same strain of the causative species after the 
end of treatment
11 21/23 (91%)
3 Do not use this as an outcome (because infections may be polyclonal hampering same/new classification 
and/or poorly standardised typing methods)
9
Reinfection
1 The emergence of multiple positive cultures with a different strain of the causative species or a strain of a 
different species during treatment or after treatment
6
2 The emergence of at least two positive cultures with a different strain of the causative species or a 
strain of a different species after the initiation of the treatment episode
10 23/23
3 Do not use this as an outcome (because infections may be polyclonal hampering same/new classification 
and/or poorly standardised typing methods)
7
Died
1 Death due to any reason, but during NTM-PD treatment 15 22/23 (96%)
2 Death during observation 8
Unknown outcome
1 Patient is no longer seen by his/her treating physician, so follow-up of treatment outcome is not 
possible (umbrella term for “lost to follow-up” and “transfer out”)
17 23/23
2 Outcome not assessed (transferred out, no culture status at months while being in care or no post-
treatment 6 assessment)
6
Died due to NTM-PD
1 All causes of death that would not have occurred if the patient had not had pulmonary NTM disease 12 22/23 (96%)
2 Do not use this as an outcome - too hard to determine causality/relation 11
Treatment halted
1 Physician- or patient-initiated pre-term cessation of antimycobacterial treatment 23 23/23
Bold italic font indicates definitions that received the most votes in round 3. Underlined sections emphasise differences between statements.
#
: version of the definition suggested in round 3 of the voting process
¶
: number of votes received from the 23 voters in round 3
+
: level of agreement obtained among 23 voters in round 5. NTM-PD: nontuberculous mycobacterial pulmonary disease.
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